CanaQuest Files International Mentanine(R) Patent, a Scientific CBD Formulation for Mental Health

By: CanaQuest Medical Corp. via AccessWire

April 29, 2021 at 08:33 AM EDT

TORONTO, ON / ACCESSWIRE / April 29, 2021 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning Life Science/Pharmaceutical company developing formulations combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced the filing of its International Patent, trade named Mentanine®, which has demonstrated at least 10-times (10X) the efficacy compared to Pharma Grade CBD.

Mentanine® - an International CBD Excellence Award 2020 formulation was scientifically developed through preclinical trials at Western University. Results of its potential effect on anxiety, depression, PTSD, and schizophrenia have been statistically significant. Our evidence also found that this formulation targeted a specific nuclear cellular receptor involved in anti-inflammatory mechanisms indicating that this formula may also treat inflammatory disorders.

"Our CBD-based Mentanine® discovery sets the stage for substantially smaller dosages having the desired results compared to other CBD medications," stated neuroscientist Dr. Steven Laviolette, who leads a 13-member research team at Western University (Ontario, Canada). "The CBD + specific concentration of Omega-3 fatty assets increases the effects of CBD alone by improving actions on anxiety-related behaviors and improved inhibition of some specific neurochemical pathways linked to anxiety, schizophrenia, and addiction processing. By this mechanism, we believe that lower doses of CBD would be required with this formula to achieve the same efficacy attained from much higher doses of CBD by itself," he added.

Results from the Mentanine® preclinical trials highlight advantages over pure CBD products on the market today, including the FDA-approved CBD drug for treating seizures associated with Lennox-Gastaut and Dravet syndromes.

Paul Ramsay, CanaQuest's Co-Founder and President, said, "The Mentanine formulation further demonstrates the depth and breadth of our scientific research platform and goal of treating anxiety, depression, PTSD, and other debilitating ailments. To date, CBD alone has shown little scientific impact on the ability of the Central Nervous System (CNS) to help with mental health issues. We believe Mentanine® can become a ‘life-changer,' improving quality of life for many and without the side effects caused by larger CBD doses," he emphasized.

Regulatory Pathway and Drug Identification Number (DIN)
There is strong evidence from preclinical trial results that CanaQuest's modified formulation, in combination with its proprietary processing and delivery method, is also a very promising epilepsy treatment. The Company is collaborating with experienced parties to initiate the application process, including human trials to obtain approval for an Rx Drug Identification Number (DIN) for rare diseases under the umbrella of Epilepsy from the US FDA and Health Canada. The Company believes the DIN approval process time requirement will be significantly reduced, reflecting the proven regulatory pathway and previous approvals for other products containing CBD and THC.

Physicians interested in joining our network, as well as clinics and pharmacies, should register at www.canaquest.com.

Customers and patients can register at info@canaqueststore.com for updates on product developments.

CanaQuest is entering discussions with domestic and international medical cannabis distributors. Please contact us with indications of interest.

CanaQuest Medical Corp is an award-winning Life Science/Pharmaceutical company developing health and wellness products combining cannabinoid molecules with pharmaceutical-grade botanical compounds. The Company has developed two commercial-ready Master Formulations, Mentanine® and Mentabinol®, for treating mental health ailments. CanaQuest has also identified the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the USA for Epilepsy rare diseases. The modified Mentanine® formulation, in combination with its proprietary processing and delivery method, is very promising for epilepsy treatment as an Rx drug. The Company will be selling both products in the coming months to patients through ADC BioMedical Corp, its wholly-owned subsidiary, which was awarded a Cannabis Medical Sales Import/Export License from Health Canada under the Cannabis Act. CanaQuest is a leader in scientifically-backed cannabinoid products in collaboration with multiple Canadian universities including a Western University team led by Dr. Steven Laviolette, who has decades of research experience focused on novel pharmacotherapies addressing anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder (PTSD).

FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" as defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the use of proceeds and the development, costs, and results of current or future actions and opportunities in the sector. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, our ability to raise the additional funding we will need to continue to pursue our exploration and development program, and our ability to retain important members of our management team and attract other qualified personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in our annual Disclosure Statement filed with the OTC Markets for the most recent fiscal year.